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Abstract
Background: Cognitive model of panic disorder have proposed that panic attacks result from the
catastrophic misinterpretation of certain bodily sensations. Cognitive-Behavioral Therapy (CBT)
for panic disorder aims to change these catastrophic cognitions. CBT intervention successfully
caused reduction of catastrophic cognitions and symptomatic improvement in the majority of
cases. However there are some patients who fail to modify their catastrophic cognitions or rather
experience an increase in them during CBT treatment. It is clinically and theoretically important to
understand about cognitive sensitization of panic disorder during CBT sessions. The purpose of the
present study is 1) to clarify the baseline characteristics of panic patients who would experience
sensitization of their catastrophic cognitions through the CBT treatment, and 2) to examine the
course of symptomatic changes for them.
Methods: Of ninety-five outpatients with panic disorder started the group CBT program for
treatment of panic disorder, seventy-nine completer were classified as "cognitively sensitized (CS)"
or "cognitive responding (CR)" or "no-responder" according to the difference of the Agoraphobic
Cognitions Questionnaire score across treatment. We compared the CS and CR patients in terms
of their baseline clinical characteristics. Then we assessed the symptomatic and functional changes
for both groups.
Results: At the start of the CBT program, despite of the same degree of panic disorder severity,
CS scored significantly lower on ACQ score than CR. CS also showed significantly lower score on
anticipatory anxiety compared to CR. At the end of treatment CS showed significant improvement
in severity of panic disorder, although the degree of improvement was smaller than that for CR.
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their functional impairment up to three month of follow-up.
Conclusion: Panic patients who would experience sensitization of their catastrophic cognitions
through the CBT treatment could nonetheless gradually improve. They showed a relatively low
level of catastrophic cognition and anticipatory anxiety before starting the CBT program. We might
conclude that temporary sensitization of catastrophic cognition may be necessary before
improvement especially among those with initially low catastrophic body sensation fears and that
we need not be concerned too much with temporary increase in catastrophic cognition in the
process of CBT for panic disorder.
Background
A number of studies have supported the effectiveness of
cognitive behavioral therapy (CBT) for panic disorder [1-
3]. Several studies also suggested that CBT is effective
treatment for panic patients who have failed to respond to
adequate pharmacotherapy [4-7].
Cognitive model of panic disorder[8] have proposed that
panic attacks result from the catastrophic misinterpreta-
tion of certain bodily sensations. Patients have the ten-
dency to perceive essentially benign and normal
sensations as evidence of imminent danger. For example,
palpitations are misinterpreted as a signal of a heart
attack, dizziness as evidence impeding loss of control, etc.
Goldstein and Chambless [9] labelled this fear of experi-
encing anxiety or panic attacks as "fear of fear". This leads
to hypervigilance about bodily sensations, increased
arousal of the sympathetic nervous system, more physical
sensations, and heightened anxiety, which spiral into a
panic attack.
CBT for panic disorder aims to change these catastrophic
cognitions[10]. Taylor [11] reported that modifying
patients' catastrophic misinterpretations of bodily sensa-
tions results in significant reductions in panic. Although it
is unclear whether change in cognition instigates sympto-
matic change or not, many studies suggest that successful
treatment was associated with a reduction in catastrophic
cognitions [10,12-14]. These studies reported that CBT
intervention successfully caused reduction of catastrophic
cognitions and symptomatic improvement in the major-
ity of cases. However there are some patients who fail to
modify their catastrophic cognitions or rather experience
increase in them during CBT treatment. In a biological
challenge study for panic disorder patients, Beck and
Shipherd[15] found that there were two distinct response
patterns to repeated presentation of physical sensations:
habituation of fear and fear sensitization. It is clinically
and theoretically important to understand about cogni-
tive sensitization of panic disorder during CBT sessions.
However the baseline characteristics of the patient who
would sensitize their catastrophic cognition during CBT,
and the course of panic disorder for them are not well
known.
The purpose of present study is 1) to clarify the baseline
characteristics of panic patient who would experience sen-
sitization of their catastrophic cognitions through the CBT
treatment, and 2) to examine the course of symptomatic
changes for them.
Methods
Subjects
Subjects were 137 consecutive patients who sought treat-
ment for panic disorder at Nagoya City University Hospi-
tal Department of Psychiatry between June 2001 and
March 2006. Of 137 patients, 95 subjects attended the
group cognitive-behavioral therapy program.
At the start of the CBT program, all the patients met the
following entry criteria:(a) principal Axis I diagnosis of
panic disorder with or without agoraphobia according to
the DSM-IV(Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition) criteria, as assessed by the
Structured Clinical Interview for DSM-IV(SCID) [16]; (b)
absence of a history of psychosis and current substance-
use disorder; (c) highly motivated to undergo CBT.
Patients with other comorbid anxiety disorders and/or
major depressive disorders were admitted to the CBT pro-
gram after the symptoms of these disorders had abated
and they were able to participate in the program. At the
start of the CBT program, of ninety-five patients, there are
five with social phobia, 3 with obsessive-compulsive dis-
order, 3 with specific phobia, 5 with post-traumatic stress
disorder and one with generalized anxiety disorder. As for
depression at the start of the CBT program, there are three
patients with present major depressive episode and five
with dysthymic disorder.
Use of antidepressants to control their anxiety and/or
depression was permitted throughout the CBT period.
Because these drugs do not interfere with CBT treatments
[17]. In case the patients were using benzodiazepines reg-
ularly or occasionally during the daytime to control their
anxiety, we advised them to taper and stop usage or toPage 2 of 9
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gram, since these drugs may interact negatively with expo-
sure treatment [18]. Some patients reported that they had
not been able to stop taking anxiolytic benzodiazepine by
the start of the CBT program. Medications for symptoms
other than anxiety were not restricted, so patients were
allowed to use short-acting benzodiazepine hypnotic.
At the start of the CBT program, 56 patients used antide-
pressants, 19 patients used benzodiazepines regularly or
occasionally.
The Ethics Committee of Nagoya City University Gradu-
ate School of Medical Sciences approved the study proto-
col and all subjects provided written informed consent
after full explanation of the purposes and procedures of
the study.
Treatment
CBT program used in this study was based on the CBT pro-
gram developed by the Clinical Research Unit for Anxiety
and Depression at the University of New South Wales,
Sydney, Australia [19]. This treatment consists of five
major components: (a) psycho-education concerning the
nature, causes and maintenance of anxiety and panic; (b)
breathing retraining; (c) cognitive restructuring; (d)
graded situational exposure to reduce agoraphobic avoid-
ance; (e) interoceptive exposure to reduce patients' fear of
somatic sensations. Patients were assigned homework
after each session.
One group consisted of three to four patients. Two trained
therapists (psychiatrists or clinical psychologists with at
least 2 years of clinical experience) conducted two-hour
highly structured sessions once a week for ten weeks,
using a detailed manual.
The senior psychiatrist, who had more than 15 years'
experience as a clinician and had observed the PD-CBT
program at St. Vincent's Hospital, trained the other thera-
pists. With the aim of training, the junior psychiatrists or
psychologists attended a series of CBT sessions as co-ther-
apist, which facilitated mainly by the senior therapist.
Then trained junior psychiatrist or psychologist began to
lead a group CBT sessions assisted by another junior ther-
apist. The senior psychiatrist supervised the other thera-
pists at a CBT clinical conference held once a week.
Measures
Before enrolment into the CBT program, all participants
received a semi-structured interview judging the anxiety
and mood disorders section of the SCID and the Panic
Disorder Severity Scale (PDSS). This interview was con-
ducted by one of the clinicians carrying out the CBT pro-
gram. Then at the start of the program, all patients
completed five self-report questionnaires. To assess the
intensity of catastrophic cognitions, patients were asked
to fill out the Agoraphobic Cognitions Questionnaire
(ACQ). To evaluate the clinical status and personality
characteristics, patients completed the Work, Home and
Leisure Activity Scales (WHLS), the Fear Questionnaire-
agoraphobic subscale (FQ-ag), the Mobility Inventory for
agoraphobia-alone subscale (MI-alone), and the NEO-
Five Factor Inventory (NEO-FFI). The same sets of instru-
ments except for the personality inventory were repeated
at the end of the program. Three months after the end of
the program, we mailed follow-up questionnaires includ-
ing ACQ, FQ-ag, MI-alone, and WHLS. Details of these
instruments are described below. Since we followed up by
post mail, PDSS which is based on a semi-structured inter-
view was not administered at 3-month follow-up.
Agoraphobic Cognitions Questionnaire (ACQ)
The ACQ is a 14-item self-report instrument to assess "fear
of fear" or cognitions concerning catastrophic conse-
quences of experiencing anxiety. Each item is rated on a
five-point scale ranging from 1(thought never occurs) to
5(thought always occurs), according to the frequency with
which this thought occurred when the client was anxious.
Good reliability and validity have been shown for both
the original and the Japanese versions of this question-
naire[20,21].
Panic Disorder Severity Scale (PDSS)
The PDSS is a seven-item interview-based scale of panic
disorder severity in which the clinician rates the severity of
seven features of panic disorder on a scale rating from 0
(none) to 4 (extreme). The features that are rated include
frequency of panic attack, distress during panic attack,
anticipatory anxiety, agoraphobic fear/avoidance, intero-
ceptive fear/avoidance, work impairment/distress, and
social impairment/distress. Adequate inter-rater reliability
and validity have been reported for both the original and
the Japanese versions [22,23].
The Work, Home and Leisure Activities Scale (WHLS)
The Work, Home and Leisure Activity Scales was designed
to assess role functioning in the areas of work, home man-
agement, social leisure, and private leisure activities. Each
item is rated on a nine-point scale ranging from 0 (not at
all impaired) to 8 (very severely impaired). Satisfactory
reliability and construct validity have been reported [24].
Fear Questionnaire-agoraphobia subscale (FQ-Ag)
The Fear Questionnaire-agoraphobia subscale is a self-
report instrument for measuring the severity of agorapho-
bic avoidance of five typical situations for agoraphobia.
Each situation is rated on a nine-point scale ranging from
0 (would not avoid it) to 8 (always avoid it) to show how
much he/she would avoid each of the listed situationsPage 3 of 9
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reliability and factor validity have been confirmed [25].
Mobility Inventory for agoraphobia-alone subscale (MI-alone)
The Mobility Inventory for agoraphobia is a self-report
instrument for measuring the severity of agoraphobic
avoidance. Patients are asked to rate on a five-point scale
ranging from 1(never avoid) to 5(always avoid) to show
how they feel about 31 places or situations that they may
avoid because of anxiety or phobia, when they are alone.
This instrument has been shown good reliability and con-
struct validity [26,27].
NEO-Five Factor Inventory (NEO-FFI)
The NEO-FFI is a 60-item self-reported inventory aimed to
assess five personality factors of neuroticism, extraversion,
conscientiousness, openness, and agreeableness [28].
Statistical analyses
To estimate the change of catastrophic cognition, we cal-
culated the differences in ACQ total score across the treat-
ment for each subject. Then we considered the standard
error of measurement (http://www.w3.org/1998/Math/
MathML1471-244X-7-70-i1SEM=σ1−γMathType-MTEF
Math-
Type@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearu
WrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfg
asaacPC6xNi=xH8viVGI8Gi=hEeeu0xXdbba9frFj0xb9qq
pG0dXdb9aspeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr
0xfr=xfr=xc9adbaqaaeGacaGaaiaabeqaaeqabiWaaaGcba
Gaee4uam1aaSbaaSqaaiabbweafjabb2eanbqabaGccqGH
9aqpiiGacqWFdpWCdaGcaaqaaiabigdaXiabgkHiTiab=n7
aNbWcbeaaaaa@35D2@: σ = standard deviation of nor-
mal population, γ = test-retest reliability coefficient).
Since there was no available data revealing the stability of
ACQ for a Japanese sample, we calculated the SEM for ACQ
by using the data from Chambless et al.[20], and Chamb-
less[29]. Based on the calculated SEM for ACQ total score
(SEM = 2.41), we set the cut-off point at 3 as minimum
change score. Each subject was classified as a "cognitive
responding (CR)," or a "cognitively sensitized (CS)"
based on their differences of ACQ total score across the
treatment. The subject whose ACQ score at post-treatment
was 3-point or more lower than pre-treatment ACQ score
was classified as CR, and those whose post-treatment ACQ
score was 3-point or more higher than pre-treatment ACQ
score was classified as CS. Others who change the ACQ
ranged from +2 to -2 across the treatment were considered
as non-responder in cognition.
Following categorization of subjects, we compared the
demographic data and the personality traits at the start of
the CBT program among groups, using analysis of vari-
ance (ANOVA) for continuous variables and chi-squared
test of independence for categorical variables. If the data
distribution did not follow the normality assumption,
Kruskal-Wallis Test was utilized.
We then focused on the differences between the CS and
CR patients. First we compared these two groups in terms
of their baseline clinical characteristics. The group mean
values were compared using the independent Student t-
test, as long as the variables were normally distributed
within each group and the variation of scores in the two
groups were not reliably different. If the data distribution
did not follow the normality assumption, Mann-Whitney
U test was utilized.
For the assessment of changes in symptom severity and
functional impairment across treatment in both groups,
Student's t-test for dependent samples was used. If the
data distribution did not follow the normality assump-
tion, Wilcoxon rank-sum test was utilized. The within-
group treatment effect size (ES) was calculated by Cohen's
d.
Further ANOVA for repeated measures with PDSS total
score as the dependant variable was performed to evaluate
whether the degree of improvement differed between the
two groups.
To examine the course of symptomatic changes for the
two groups, we conducted a 2(group: CS vs. CR) × 3(time:
baseline vs. post-treatment vs. three-month follow-up)
repeated measures ANOVA with FQ-ag score, MI-alone
score and WHLS as the dependant variable, followed by
the post-hoc Dunnett's test when appropriate. All data
undergoing ANOVA were tested for assumption of
sphericity with Mauchly's test. In cases the sphericity did
not hold, we adjusted the degree of freedom for the F-test
using the Greenhouse-Geisser epsilon.
Statistical analyses were performed using the SPSS pro-
gram version 15.0. All the statistical tests were two-tailed,
and results were considered significant when p < 0.05.
Results
Of ninety-five patients who started the CBT program, six-
teen patients withdrew from the program before its com-
pletion, because of symptom improvement, lack of
improvement, inconvenience of attending the program,
concurrent physical illness or worsening of depression.
The seventy-nine completers (26 men and 53 women)
with a mean age of 36.1(SD = 11.3) were classified as
CS(N = 11) or CR(N = 52) or no-responder(N = 16)
according to the difference of ACQ score across the treat-
ment. Table 1 presents baseline sample demographic and
personality characteristics. At the start of the CBT pro-
gram, there were no significant differences between the
four groups.Page 4 of 9
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patients at baseline. CS patients scored significantly lower
on the ACQ than CR patients. The mean score of PDSS
(11.1 for CS, 13.2 for CR) indicated a high-to-moderate
level of panic disorder severity for both groups and the
total scores were not significantly different at baseline
between the two groups. On the item level, frequency of
panic attack, distress of attack, agoraphobic fear/avoid-
ance, and impairment of work or social functioning did
not differ significantly. However, CS patients presented a
significantly lower score than CR patients on anticipatory
anxiety and non-significant trend to a lower score on inte-
roceptive fear/avoidance. The scores of FQ-ag, MI-alone
and WHLS did not differ between the groups.
By definition, as can be seen in Table 3, ACQ scores
increased significantly across treatment among CS
patients. The mean score of ACQ moved from 22.9(SD =
4.7, range: 18 to 33) at baseline to 27.7(SD = 5.0, range:
21 to 36) at endpoint. For CR patients, ACQ score
Table 1: Baseline demographic and personality characteristics of the subjects
Cognitively sensitized
(N = 11)
Cognitive responding
(N = 52)
No-response in cognition
(N = 16)
Drop-out from treatment
(N = 16)
Female 6(54.5%) 34 (65.4%) 13(81.3%) 12(75.0%)
With agoraphobia 10(90.9%) 49(94.2%) 14(87.5%) 15(93.8%)
Mean age (SD)a 37.5(13.3) 35.0(9.7) 38.9(14.4) 34.5(11.4)
Mean age at onset of PD (SD)a 28.3(13.8) 29.8(9.7) 39.9(12.8) 29.1(9.4)
Mean yeas of duration of panic disorder 
(SD)a
9.2(12.1) 5.2(5.1) 9.1(11.7) 5.4(6.2)
Severity of panic disorder: PDSSb total 
score at baseline (SD)a
11.1(4.1) 13.2(4.7) 9.3(4.5) 12.5(4.9)
Medication at start of CBT session
Antidepressants 9(81.8%) 31(59.6%) 9(56.3%) 7(43.8%)
Benzodiazepines 5(45.5%) 9(17.3%) 3(18.8%) 2(12.5%)
NEO-FFIc(SD)
Neuroticism 22.6(11.8) 28.1 (7.6) 22.3(9.4) 27.5(8.7)
Extraversion 25.6(11.0) 25.6(6.7) 28.3(9.6) 26.2(10.3)
Openness 25.2(9.4) 27.6(5.9) 26.1(5.6) 30.4(5.8)
Agreeableness 31.6(10.6) 32.1(7.2) 36.7(6.1) 30.4(5.1)
Conscientiousness 24.8(12.4) 28.6(6.7) 27.5(8.0) 28.3(9.3)
No significant differences for all comparisons.
a:SD = Standard Deviation b:PDSS = Panic Disorder Severity Scale
c:NEO-FFI = NEO-Five Factor Inventory
Table 2: Clinical status at baseline by group
Group p*
CSa(n = 11) Mean(SD) CRb(n = 52) Mean(SD)
ACQc 22.9(4.7) 30.8(8.8) .003
PDSSd total score 11.1(4.1) 13.2(4.7) .160
frequency of panic 1.1(0.5) 1.3(0.9) .574
distress duringpanic 2.4(1.1) 2.5(1.3) .655
anticipatory anxiety 1.2(1.1) 1.9(1.0) .041
agoraphobic fear/avoidance 2.0(1.0) 2.2(1.1) .548
interoceptive fear/avoidance 0.6(0.8) 1.2(1.1) .078
impairment of work functioning 1.82(1.2) 2.1(1.1) .572
impairment of social functioning 2.0(1.0) 2.1(1.1) .785
FQ-age 13.6(12.2) 13.2(9.8) .971
MI-alonef 2.4(0.9) 2.6(1.0) .615
WHLSg 11.3(8.3) 10.9(5.4) .894
*:Student's t-test for independent samples or Mann-Whitney U test
a: CS = Cognitively sensitised b: CR = Cognitive responding
c:ACQ = Agoraphobic Cognitions Questionnaire, d:PDSS = Panic Disorder Severity Scale, e:FQ-ag = Fear Questionnaire-agoraphobia subscale, 
f:MI-alone = Mobility Inventory for agoraphobia-alone subscale, g:WHLS = The Work, Home and Leisure Activities ScalePage 5 of 9
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from 30.8(SD = 8.8, range: 18 to 56) at baseline to
20.7(SD = 6.1, range: 14 to 42) at endpoint.
For both groups, PDSS total scores improved significantly;
CS patients' mean score moved from 11.1(SD = 4.1) at
baseline to 9.1(SD = 4.4) at endpoint. CR patients' mean
score moved from 13.2(SD = 4.7) at baseline to 5.9(SD =
4.3) at endpoint. Repeated measures ANOVA for PDSS
total score showed a significant main effect of time
(F(1,60) = 32.239, p < 0.001), and Group × Time interac-
tion (F(1,60) = 10.80, p = 0.002). The degree of improve-
ment differed between two groups.
With regard to symptomatic and functional changes
across treatment, CR patients showed significant improve-
ment for all variables. In contrast, CS patients significantly
improved in impairment of social functioning and WHLS,
and showed non-significant trend to improve in MI-
alone.
Results of repeated measures ANOVA which examined the
courses of symptomatic changes from baseline to three
month follow-up for the two groups are presented in
Table 4. For all variables, we found a significant main
effect of time and no significant Group × Time interaction.
As can be seen in Table 5, post hoc Dunnett tests revealed
that post-treatment scores of CR patients were signifi-
cantly reduced compared to baseline scores for all meas-
ures. And 3-month follow-up scores of CR patients were
also significantly reduced compared to baseline scores. In
contrast, at the end of the program CS patients showed
non-significant trend to reduce their post-treatment scores
in MI-alone and WHLS, and did not show significant
reduction in FQ-ag. Whereas compared to baseline scores,
3-month follow-up scores of CS patients were signifi-
cantly reduced for FQ-ag and MI-alone, and showed non-
significant trend to be reduced for WHLS.
Discussion
With regard to the first objective of the present study, we
were able to delineate the baseline characteristics of panic
patient who would experience sensitization of their cata-
strophic cognitions through the CBT treatment as follows.
Despite the same degree of panic disorder severity, CS
patients showed relatively low level of catastrophic cogni-
tions than CR patients preceding CBT treatment. Further-
more, CS patients reported lower level of anticipatory
anxiety and interoceptive fear/avoidance before treat-
ment. These findings are generally consistent with prior
research conducted by Beck & Shipherd[15] who found
that panic disorder patients who showed fear sensitization
during repeated CO2 inhalation sessions had shown a rel-
atively low level of anticipatory anxiety preceding CO2
inhalation.
The second purpose of this study was to examine the
course of symptomatic change of CS patients. We found
that at the end of treatment CS patients showed signifi-
cant improvement in severity of panic disorder, although
the degree of improvement was smaller than that for CR
patients. The improvement for CS patients at the end of
treatment was mainly due to restoration of social func-
tioning. This improvement for CS patients appears to con-
tinue at least for three months following the end of
treatment. Consistent with previous findings
[3,11,14,30], CR patients were significantly and clinically
Table 3: Changes of panic symptoms across the treatment, including effect sizes
Cognitive I y Sensitized patients (N = 11) Cognitive Responding patients (N = 52)
Baseline Post-treatment pa Effect sizeb Baseline Post-treatment pa Effect sizeb
ACQc 22.9(4.7) 27.7(5.0) .<000 -2.34 30.8(8.8) 20.7(6.1) <0.00 1.59
PDSSd-total 11.1(4.1) 9.1(4.4) .047 0.62 13.2(4.7) 5.9(4.3) <0.00 1.41
PDSSd-item <0.00
frequency of panic 1.1(0.5) 0.9(0.5) .317 0.30 1.3(0.9) 0.8(0.8) <0.00 0.56
distress duringpanic 2.4(1.1) 2.4(1.1) .732 0.03 2.5(1.4) 1.4(1.1) <0.00 0.70
anticipatory anxiety 1.2(1.1) 1.1(0.6) .792 0.08 1.9(1.0) 0.8(0.8) <0.00 1.01
agoraphobic fear/avoidance 2.0(1.0) 1.5(0.8) .107 0.53 2.2(1.1) 0.9(0.9) <0.00 1.08
interoceptive fear/avoidance 0.6(0.8) 0.7(0.9) .603 -0.15 1.2(1.1) 0.5(0.8) <0.00 0.60
impairment of work functioning 1.8(1.2) 1.5(1.3) .206 0.39 2.1(1.2) 0.7(1.2) <0.00 1.03
impairment of social functioning 2.0(1.0) 1.1(1.1) .039 0.74 2.1(1.1) 0.9(1.0) <0.00 1.08
FQ-age 13.6(12.2) 10.6(8.2) .153 0.42 13.2(9.8) 5.1(6.4) <0.00 0.79
MI-alonef 2.4(0.9) 2.1(0.7) .070 0.61 2.6(1.0) 1.7(0.7) <0.00 1.59
WHLS g 3.2(2.1) 2.4(1.8) .026 0.78 2.7(1.4) 1.3(1.3) <0.00 0.53
a: Student's t-test for dependent samples or Wilcoxon rank-sumtest, b: Within-group effect size (ES) by Cohen's d. c:ACQ = Agoraphobic 
Cognitions Questionnaire, d:PDSS = Panic Disorder Severity Scale, e:FQ-ag = Fear Questionnaire-agoraphobia subscale, f:MI-alone = Mobility 
Inventory for agoraphobia-alone subscale, g:WHLS = The Work, Home and Leisure activities ScalePage 6 of 9
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tinue to improve up to three month follow-up. In con-
trast, CS patients showed lower improvement compared
to CR patients at the end of program, but then they would
progressively reduce their agoraphobic fear and avoid-
ance, and would improve their functional impairment up
to three month of follow-up.
It is interesting to note that panic patients who would
experience sensitization of their catastrophic cognitions
through the CBT treatment could nonetheless gradually
improve. It has already been pointed out that exposure to
feared situations or bodily sensations can initially increase
anxiety. Otto et al. emphasized that these experience help
patients to learn that they can be "OK" despite the pres-
ence of anxiety [3]. We may then be able to postulate that
CS patients had been taking the strategy of cognitive
avoidance of the threat cues before attending CBT treat-
ment. Koster et al. reported the paradoxical effects of sup-
pressing anxious thoughts [31]. They found that during
thought suppression, self-reported anxiety and frequency
of anxious thoughts did not increase, and duration of anx-
ious thoughts decreased. After thought suppression, par-
ticipants experienced an increase in self-reported anxiety
and the frequency of anxious thoughts. Thus for anxious
patients the strategy of cognitive avoidance might play a
role in maintaining anxiety disorder. When cognitive
avoidance is present, then sensitization of catastrophic
cognitions might be clinically meaningful in CBT for
panic disorder.
Several limitations of current study should be mentioned.
First, the procedure of categorization that classified
patients into "cognitively sensitized" or "cognitive
responding" may appear rather arbitrary. A different cate-
gorization strategy may have been possible but in the
absence of agreed-upon procedure, we set the SEM as the
cut-off point. Second, the sample size was rather small to
generalize our results and some of our negative findings
might be due to lack of power. However, we can be sure
of what positive findings we were able to identify. Third,
the study did not include a control group and one cannot
be sure if the significant reduction in panic symptomatol-
ogy observed in the present cohort might be due to pas-
sage of time rather than to CBT treatment per se. Fourth,
we did not confirm the change of symptomatorogy for
depression with objective measure during the treatment
and follow-up phase. Therefore we could not perfectly
exclude the possibility that the results of this study
affected any symptom of depression. Fifth, we did not
Table 4: Results from repeated measure ANOVA for Change of panic symptoms
p-value result from repeated measure ANOVA
Dependant variable Time Group Interaction
FQ-aa <0.00 0.44 0.39
MI-aloneb <0.00 0.93 0.11
WHLSc <0.00 0.04 0.38
a:FQ-ag = Fear Questionnaire-agoraphobia subscale, b:MI-alone = Mobility Inventory for agoraphobia-alone subscale, c:WHLS = The Work, Home 
and Leisure activities Scale
Table 5: Changes of panic symptoms at endpoint and 3-month follow-up
Dependant variable Time CSa CRb
mean(SD) p-value* mean(SD) p-value*
FQ-agc baseline 13.6(12.2) 13.2(9.8)
end-point 10.6(8.2) 0.33 5.1(6.4) <0.00
3 month-f/u 7.3(7.7) 0.04 4.7(6.3) <0.00
MI-aloned baseline 2.4(0.9) 2.6(1.0)
end-point 2.1(0.7) 0.09 1.7(0.7) <0.00
3 month-f/u 1.8(0.8) 0.001 1.8(0.9) <0.00
WHLSe baseline 3.2(2.1) 2.7(1.4)
end-point 2.4(1.8) 0.05 1.3(1.3) <0.00
3 month-f/u 2.4(1.8) 0.09 1.3(1.5) <0.00
*:Result from post hoc test using Dunnett' method
a: CS = Cognitively sensitised b: CR = Cognitive responding c:FQ-ag = Fear Questionnaire-agoraphobia subscale, d:MI-alone = Mobility Inventory 
for agoraphobia-alone subscale, e:WHLS = The Work, Home and Leisure activities ScalePage 7 of 9
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in the post treatment follow-up phase. Therefore strictly
we couldn't rule out the possibility the improvement of
patients due to some other treatment.
Casey et al.[12] concluded in their study that it is neces-
sary to include measures of positive cognitions (e.g. self
efficacy in dealing with anxiety thought) in assessing the
impact of catastrophic cognitions. We didn't address the
positive cognitions in this study. Further research will be
needed to investigate how self efficacy changes, especially
in CS patient.
Conclusion
In conclusion, we found that CS patients had a lower level
of catastrophic cognition and anticipatory anxiety than
CR patients at baseline before starting the CBT program.
Through and at three months after the CBT program, CR
patients demonstrated robust and continued improve-
ment in symptomatology and functioning, while CS
patients lagged behind CR patients, because they scored
worse at the end of acute phase treatment than CR
patients but tended to catch up with them at three-month
follow-up. When clinically paraphrased we might con-
clude that temporary sensitization of catastrophic cogni-
tion may be necessary before improvement especially
among those with initially low catastrophic body sensa-
tion fears and that we need not be concerned too much
with temporary increase in catastrophic cognition in the
process of CBT for panic disorder.
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